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Modulation of renin-angiotensin system (RAS) by angiotensin-(1–7) (Ang-(1–7)) is an attractive approach to combat the
detrimental consequences of myocardial infarction (MI). However Ang-(1–7) has limited clinical potential due to its unfavorable
pharmacokinetic profile. We investigated eﬀects of a stabilized, thioether-bridged analogue of Ang-(1–7) called cyclic Ang-(1–7) in
rat model of myocardial infarction. Rats underwent coronary ligation or sham surgery. Two weeks thereafter infusion with 0.24 or
2.4 μg/kg/h cAng-(1–7) or saline was started for 8 weeks. Thereafter, cardiac morphometric and hemodynamic variables as wells
as aortic endothelial function were measured. The average infarct size was 13.8% and was not changed by cAng-(1–7) treatment.
MI increased heart weight and myocyte size, which was restored by cAng-(1–7) to sham levels. In addition, cAng-(1–7) lowered
left ventricular end-diastolic pressure and improved endothelial function. The results suggest that cAng-(1–7) is a promising new
agent in treatment of myocardial infarction and warrant further research.
1. Introduction
Myocardial infarction is a leading cause of mortality and
morbidity in western society. Current intervention relies on
prevention of myocardial hypertrophy and fibrosis and of
thrombosis. Since these processes are partially mediated by
an increase of the renin-angiotensin system (RAS) hormone;
angiotensin (Ang) II, inhibition of this hormone through
drugs; that decrease its production or its signaling via the
Ang II type 1 (AT1) receptor; forms an important part of the
applied pharmacotherapy. The ever culminating knowledge
of RAS; brought about by relentless research of a vast
group of scientists; has raised the awareness that there is
more to achieve than with classical RAS intervention only.
Possible novel intervention strategies have emerged, of which
those based on stimulation of angiotensin-(1–7) (Ang-(1–7))
function as one of the most appealing [1, 2].
Angiotensin-(1–7) (Ang-(1–7)) is a hormone that in gen-
eral counteracts Ang II through its own signaling pathways,
which involves the Mas receptor [3]. Studies in animal
models show that it has ample therapeutic potential in
cardiovascular disease, in particular diseases that are featured
by malignant remodeling of the heart. We showed that
chronic infusion of Ang-(1–7) in rats or mice with myocar-
dial infarction improves cardiac and endothelial function
[4, 5]. The beneficial eﬀect of Ang-(1–7) infusion after
myocardial infarction relies on the versatile bioactivity of
the hormone, which comprises antihypertrophic, -fibrotic,
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and -thrombotic function, improvement of eNOS function,
blockade of Ang-II-induced ROS production, and stimu-
lation of endothelial-progenitor-cell-mediated angiogenesis
[1, 2, 5–9]. In spite of being a therapeutic prodigy, Ang-
(1–7) does not oﬀer ideal prospects for clinical use because
of its pharmacokinetical and pharmacodynamical properties
(as is also elaborated in [1]). Firstly, the peptide is rapidly
metabolised in plasma and tissue. Second, beneficial eﬀects
of Ang-(1–7) take place at low concentrations at which
Mas receptors are stimulated. At higher concentrations Ang-
(1–7) becomes aspecific for receptor subtype binding, being
a partial Ang II type 1 receptor agonist and an Ang II type
2 receptor agonist. Thus, overdosing might interfere with its
Mas receptor-associated functions.
To improve the pharmacological profile we have devel-
oped cyclic Ang-(1–7) (cAng-(1–7)), an Ang-(1–7) analogue
in which amino acid residues 4 and 7 have been linked with
a thioether bridge, thus forming a lanthionine [10]. The
strategy of thioether bridging is used by bacteria to stabilize
peptides, and we previously showed that enzymatically syn-
thesized cAng-(1–7) was fully resistant against degradation
by angiotensin-converting enzyme and had enhanced resis-
tance against breakdown by other proteases. It displayed 34-
fold enhanced presence in the blood circulation in Sprague-
Dawley (SD) rats during continuous intravenous infusion.
The thioether ring did not prevent cAng-(1–7) from ago-
nistically interacting with the Mas receptor, the receptor
of native angiotensin-(1–7). cAng-(1–7) even induced a
twofold larger relaxation of precontracted SD rat aorta rings
than native Ang-(1–7). Moreover, it is a specific agonist for
Ang-(1–7) receptors. Therefore, cAng-(1–7) holds promise
for use in cardiovascular therapy. In this study we have tested
the eﬀect of chronic cAng-(1–7) infusion on hemodynamic
function after myocardial infarction in the rat.
2. Methods
2.1. Animals. Male Sprague-Dawley rats weighing 280–300
grams were obtained from Harlan (Horst, the Netherlands).
Animals were put on standard rat chow and water, available
ad. libitum. Housing was at room temperature with a 12 h
light–12 h dark cycle. After at least one week of acclima-
tization in the caretaking facility, the rats were operated
to induce left ventricular myocardial infarction (MI) or
underwent a sham procedure.
2.2. Surgery to Induce MI and Surgical Procedures. Prior to
surgery 0.01mg/kg buprenorphine was given subcutaneously
for postoperative analgesia, which was repeated after surgery
for 2 days, 2 times daily. Operations were performed under
2.5% isoflurane in air ventilation anesthesia for which the
rats were intubated. Through an opening in the left 4th
intercostal space of the chest, MI was induced by ligation of
the left coronary artery with a 6/0 silk suture. After induction
of MI, as witnessed by bleaching of the myocardium,
the chest was closed and animals were withdrawn from
anesthesia. Sham-operated animals (SHAM) underwent an
identical procedure, however, without tying the silk suture
to close the coronary artery. MI surgery was performed in
106 animals, 8 animals were sham-operated. Perioperative
mortality was 45% in the MI group.
2.3. Treatment with cAng-(1–7). Two weeks after induction
of MI, rats were randomly allocated to intravenous infusion
of either 0.24 (low dose or low cAng-(1–7)) or 2.4 μg/kg/h
(high dose or high cAng-(1–7)) of cAng-(1–7) n = 12
for each dose), or of saline (n = 25) by 4-week osmotic
minipumps (Alzet model 2004). Sham-operated controls
(n = 8) received saline or high dose of cAng-(1–7)
(2.4 μg/kg/h). Animals were infused for 8 weeks, changing
pumps at week 4. To accomplish intravenous infusion a
polyethylene tube was implanted in the left jugular vein.
cAng-(1–7) was made by BiOMade/LanthioPep, Groningen.
2.4. Measurements of Hemodynamic and Vascular Function.
After 8 weeks of treatment animals were weighed (body
weight: BW) and hemodynamic studies were performed
under isoflurane anesthesia (2.5% in air) with a 2F catheter-
based, microtip pressure transducer (Millar, Houston, Tex,
USA) that was introduced into the left ventricle via intra-
luminal passing through the right carotid artery. Rats
were anesthetized for 20 minutes before the start of the
measurement.
After measurement of hemodynamic function the heart
was excised for histological studies. After removal of ventric-
ular blood; the heart was weighed to obtain total heart weight
(HW). The thoracic aorta was isolated to perform functional
studies. To this end the aorta was kept in Krebs solution in
mmol/L: NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4
1.2, NaHCO3 25 and glucose 8.3; pH 7.4. Surrounding
periaortic adipose tissue was carefully removed with small
scissors. Rings of 2mm length were cut andmounted in small
wire organ baths containing Krebs at 37◦C. To investigate
the contribution of dilator signaling factors nitric oxide
(NO) production was blocked using L-NAME (100 μmol/L),
and endothelium-derived hyperpolarizing factor (EDHF)
was blocked with apamin (0.5 μmol/L) and charybdotoxin
(0.1 μmol/L). Subsequently, in the absence or presence of
these inhibitors, concentration-response curves were con-
structed tomethacholine and SNP after preconstruction with
phenylephrine. All chemicals were from Sigma-Aldrich, the
Netherlands.
2.5. Histology. Midventricular slices of the heart were fixed
with 4% formaldehyde, embedded in paraﬃn and processed
for histochemical analysis. Infarct size was determined on
picrosirius red/fast green-stained sections and was expressed
as the percentage of scar length of the average of left
ventricular internal and external circumference. Rats with
all infarct sizes were included in the analysis. The cross-
sectional area of the individual cells was measured on
gomori-stained sections. Myocyte density was determined by
assessment of the number of cells per tissue area for each slide
and subsequent conversion to mm2. Fibrosis was measured
on picrosirius red/fast green-stained sections from three
randomly selected regions of the surviving myocardium.
2.6. Statistical Analysis. Data are presented as mean ± SEM.
Statistical diﬀerences between the groups were evaluated by
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Table 1: Weight, basic histological and cardiac parameters.
Sham MI Sham MI MI
saline saline high cAng-(1–7) low cAng-(1–7) high cAng-(1–7)
BW, g 477.1 ± 6.6 475.3 ± 6.4 484.6 ± 7.4 458.6 ± 10 492.3 ± 9.5
Infarct size, % 0 ± 0 15.853 ± 3.17 0 ± 0 9.721 ± 2.89 14.535 ± 4.10
Fibrosis, % 3.896 ± 0.57 3.992 ± 0.39 4.289 ± 0.54 4.695 ± 0.65 4.479 ± 0.34
HR beats/min 255.12 ± 16.0 260.3 ± 5.5 240.4 ± 9.8 274.7 ± 6.2 266.7 ± 6.2
MaxP, mmHg 107.8 ± 3.8 103.5 ± 2.9 98.6 ± 8.3 93.0 ± 4.7 96.4 ± 4.7
ESPress, mmHg 103.6 ± 4.2 100.1 ± 3.0 93.5 ± 9.3 89.4 ± 5.3 92.4 ± 5.1
dpdtMax, mmHg/sec 5572.0 ± 188.2 5456.8 ± 198.7 5533.0 ± 530.7 5026 ± 269.3 5111.3 ± 345.1
dpdtMin, mmHg/sec −5189.1 ± 178.8 −4919.1 ± 265.2 −6123.5 ± 1268.9 −4615.4 ± 361.8 −4742.6 ± 404.9
N 8 25 5 12 12
t-test or by 1-way ANOVA for hemodynamic and histological
variables, using Dunnett’s t-test or Bonferroni correction
where appropriate. One-sided testing was applied in all
bar graphs as the eﬀects were in the expected direction.
For testing of trend; linear regression analysis was applied.
Diﬀerences in concentration-response curves to metha-
choline were tested by general linear model ANOVA for
repeated measures. Diﬀerences were considered significant at
P < 0.05.
3. Results
3.1. Weight and Histological Characteristics. General param-
eters at the end of treatment are shown in Table 1. No
diﬀerences were observed in body weight between the 4
groups.
Infarct sizes were in general small and did not diﬀer sig-
nificantly between the cAng-(1–7) and saline-treated group.
Similarly, fibrosis did not diﬀer between the groups (Table 1).
Despite the small infarct sizes total heart weight to body
weight ratio has modestly but significantly increased in
saline-treatedMI group compared with SHAM (Figure 1(a)).
Both doses of cAng (1–7) abolished the significant diﬀerence
between MI and SHAM. However, only the higher dose
of 2.4 μg/kg/h cAng-(1–7) resulted in a lower heart weight
compared to saline, though not significantly diﬀerent.
To further determine the cause of the weight diﬀer-
ences the eﬀect of cAng-(1–7) on myocyte size measured.
Myocardial infarction increased myocyte cross-sectional area
and decreased myocyte cell density (Figures 1(b) and 1(c)).
Treatment with both doses of cAng-(1–7) restored myocyte
cross-sectional area to the level of saline-treated sham
(Figure 1(b)). Myocyte density was only restored by the
higher dose of cAng-(1–7) (Figure 1(c)). In sham-operated
animals, cAng-(1–7) treatment showed a trend towards a
decrease in myocyte size, but this eﬀect did not reach a
statistical significance (Figures 1(b) and 1(c)).
3.2. Hemodynamics. After 8 weeks of treatment, cardiac
function was measured in vivo in anesthetized rats. In
accordance with the small infarct size, cardiac function
was not significantly impaired in untreated MI rats as
compared with SHAM (Table 1). In agreement with the
absence of systolic or diastolic heart failure MI did not
significantly change left ventricular end diastolic pressure
(LVEDP) or left ventricular minimal pressure (Pmin) (t-test,
P = 0.199 for LVEDP; P = 0.090 for Pmin), and therefore
the eﬀect of cAng-(1–7) was tested within the MI and sham
group, respectively (Figure 2). In the MI group, cAng(1–7)
treatment lowered LVEDP which was significant at the
highest doses (Figure 2(a)). Since there seemed to be a dose-
dependent eﬀect we tested for a trend line, which resulted in a
significance for trend. Pmin seemed also to be lowered in MI
animals, but this eﬀect did not reach statistical significance
(Figure 2(b)). In sham animals, cAng-(1–7) given at a doses
of 2.4 μg/kg/h lowered both LVEDP and Pmin (Figures 2(a)
and 2(b)). All other measured pressure variables were not
changed by cAng-(1–7) treatment as compared to MI saline
(Table 1).
3.3. Endothelial Function. Endothelial dysfunction is a key
feature in the development of heart failure after MI since
it contributes to the increase of peripheral vascular resis-
tance that leads to increased cardiac workload resulting in
hypertrophy and contractile dysfunction of the myocardium.
Therefore, we investigated endothelium-dependent relax-
ation in isolated aortic rings.
Phenylephrine (1 μmol/L) caused similar contractile
responses in all groups (data not shown). The responses
of aortic rings to endothelium independent vasodila-
tor SNP were not changed between groups (data not
shown). Responses to the endothelium-dependent vasodila-
tor methacholine were unchanged in saline-treated MI
animals when compared with SHAM (data not shown).
However, both doses of cAng (1–7) showed increased
responsiveness to methacholine when compared to saline-
treated MI group, which was most pronounced and only
significant in the higher dose (Figure 3(a)). After blocking
the NO production of endothelium with L-NAME, the
response to methacholine was greatly suppressed in all the
groups, however the increased responsivity of high-dose
cAng (1–7) treated animals remained present (Figure 3(b)).
After blocking both NO and EDHF, leaving prostaglandins
as the remaining dilator factor, the diﬀerence between saline
and cAng-(1–7)-treated animals disappeared (Figure 3(c))
indicating that cAng works via EDHF.
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Figure 1: Comparison of heart weight/body weight ratios between the diﬀerent treatments (a), variables of cardiac hypertrophy: myocyte,
cross-sectional area (b), and myocyte density (c). (∗P < 0.05, One way ANOVA, Dunnett’s post hoc testing).
4. Discussion
Stimulation of the Ang-(1–7)/Mas receptor axis is a promis-
ing therapeutic strategy for treatment of MI and prevention
of heart failure. For this purpose we tested the eﬀect of
the metabolically protected and Mas receptor-specific com-
pound cAng-(1–7). Given at doses that were, respectively,
10 and 100 times lower than the minimally eﬀective doses
of native Ang-(1–7) [11], cAng-(1–7) dose-dependently
lowered left ventricular weight and diastolic pressure in an
MI model in which no contractile failure had yet occurred.
The eﬀect on cardiac weight seemed to depend at least
partially on reduction of cardiomyocyte hypertrophy, as
evidenced by the decrease inmyocyte dimensions. The eﬀects
on the heart morphology and function were independent
from the presence of an infarction since they also occurred
in sham animals. In addition to eﬀects on the heart,
cAng-(1–7) improved peripheral endothelium-dependent
vasodilation, as measured in isolated aortic rings; an eﬀect
that predominantly involved EDHF. cAng-(1–7) therefore
shows favorable characteristic with regard to improvement
of cardiovascular function after MI.
The present results with respect to cardiac improvement
are in accordance with previous results in the MI model
obtained after infusion of native Ang-(1–7) [4, 5]. A limita-
tion of the present study, however, is the fact that infarct sizes
International Journal of Hypertension 5
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Figure 2: Eﬀects of cAng 1–7 on left ventricular end-diastolic pressure and minimal pressure in both sham-operated rats and rats with
myocardial infarction. (#P < 0.05 t-test sham saline versus sham cAng-(1–7); ∗P < 0.05, One way ANOVA for MI groups, Dunnett’s post
hoc testing; $P < 0.05 for linear trend for MI groups).
were relatively small as compared to the previous studies,
thus not allowing us to study possible beneficial eﬀects of
the compound on systolic function and cardiac fibrosis [4,
12, 13]. Nevertheless, the implications of the present study
are relevant since patient populations also comprise subjects
with relatively small infarct sizes but who will eventually
develop heart failure, albeit after a relatively longer period.
The full potential of cAng-(1–7) as an experimental drug can
be appreciated from evaluation in a model of heart failure or
cardiac fibrosis. The present data warrant such studies.
Endothelial dysfunction is an important hallmark in
heart failure caused by MI and is believed to be pivotal in
malignant cardiac remodeling due to increased afterload.
Ang-(1–7) was shown to restore endothelium-dependent
vasodilator function in heart failure, after stent placement,
after a high salt diet and in the atherosclerosis-prone
ApoE knockout mouse when infused chronically [4, 11,
14, 15]. Vascular upregulation of ACE2, which increases
Ang-(1–7) levels, improves endothelial function in hyper-
tensive rats [16]. Conversely, Mas receptor knockout or
chronic treatment with A779, an antagonist of Mas receptor-
associated eﬀect diminishes endothelial function [17–19].
In accordance with the suggested role of Mas receptor
signaling in improvement of endothelial function cAng-
(1–7) infusion led to improved endothelial function in our
rats with smallMI. The improvement that was observed by us
appears to be mainly caused by an increase of endothelium-
derived hyperpolarizing factor (EDHF), and not through
prostaglandin release. In a previous study, which involved
relatively older rats that developed endothelial dysfunction
after stent placement, chronic infusion of native Ang-(1–7)
mainly increased prostaglandin [20]. Furthermore, short-
term infusion of the native peptide improves the hypotensive
response to acetylcholine through NO signaling, whilst Mas
receptor knockout results in impaired NO bioavailability
[19, 21]. Thus, the model that is used for studying the eﬀect
of Ang-(1–7) mediated seems to determine the signaling
pathway that is improved. Our present results are to our
knowledge the first to show an increased contribution of
EDHF and emphasize the versatility of the therapeutic poten-
tial of the Ang-(1–7)/Mas receptor axis towards endothelial
function.
As noted above, cAng-(1–7) was intravenously admin-
istered by osmotic minipump in a dose that was 10 to 100
times lower than in previous studies the lowest eﬃcacious
dose for native Ang-(1–7). This approach allowed us to
make comparisons with these previous studies and indicate
that the pharmacological properties of cAng-(1–7) seem
to be superior to those of native Ang-(1–7). To provide
conclusive evidence it will be necessary to test cAng-(1–7) in
a model of heart failure. Furthermore, a clinically relevant
method of drug delivery will have to be developed. Most
commonly, clinically applicable peptides are administered
subcutaneously where the peptide is not degraded and which
allows manipulation of the rate of peptide release, such as
in the case of insulin formulations. In a recent study it
was shown that subcutaneous cAng-(1–7) resulted in a 98%
bioavailability. Although less eﬃcient, oral and especially
pulmonary delivery (28% bioavailability) of cAng-(1–7)
appeared possible too. Therefore translation to the clinic is
6 International Journal of Hypertension
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Figure 3: Endothelial-dependent dilator function of rat aorta to metacholine (a), after blockade of eNOS/NO signaling (b), and after
combined blockade of eNOS/NO and EDHF vasodilator mechanisms (c). (∗P < 0.05, GLM-RM).
feasible [22]. There are other approaches to design a clinically
relevant delivery method to exploit the Ang-(1–7)/Mas axis.
These designs fall into four main categories: local delivery of
the native peptide, nonpeptide analogues, protective incap-
sulation of the native peptide, and upregulation of the Ang-
(1–7)-synthesizing enzyme ACE2. Local delivery is an elegant
way to circumvent loss of bioavailability of Ang-(1–7). This
approach has been explored to counteract problems that are
associated with stent placement and has led to prevention
of endothelial dysfunction [23]. Theoretically, this strategy
should also be applicable for solid tumors. Peptide incapsula-
tion includes PEG-liposome complexes that can be delivered
intravenously [23], but most promising appears to be the use
of hydroxypropyl β-cyclodextrin, which has led to successful
cardioprotection after infarction or chronic isoproterenol
infusion in rats when delivered orally [24]. Nonpeptide
analogues include AVE 0991 and CGEN-856S, which show
vasodilatory and cardioprotective properties (less arrythmias
during recovery from I/R) in vitro, and antihypertensive
eﬀects in vivo [23, 25]. However, oral delivery has not
been attempted with these compounds. Last, upregulation
of ACE2 has been successfully attempted as intervention
in cardiac and pulmonary fibrosis models, and in Ang-II-
dependent renal fibrosis. Of particular interest is the use of 1-
[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-
methylphenyl) sulfonyl oxy]-9H-xanthene-9-one (XNT), an
ACE2 ligand and activator of the enzyme. Until present, XNT
was shown eﬀective against cardiac and pulmonary fibrosis
and against pulmonary hypertension when administered
subcutaneously with minipumps [26, 27].
In summary, we here present the first data showing that
lanthionine-bridged Ang-(1–7), shortly cAng-(1–7), holds
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promise as a therapeutic agent after MI, as it improves
cardiac remodeling and endothelial function and since it has
previously [22] been demonstrated that it can be delivered
orally and pulmonarily. Our present results warrant further
testing of this compound in various models of heart failure
and possible other diseases that can be a target of beneficial
Ang-(1–7)/Mas receptor axis signaling.
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